BridgeMD
New treatment option for Type 1 Diabetes (T1D)
Official title Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction
ClinicalTrials.gov ID: NCT07507708
What this study is testing
- What it's testing
- This study is a randomized cross-over trial comparing AIDANET with Anticipation to AIDANET in FCL without Anticipation. Participants will complete 4 weeks of AID data collection which will be used to establish baseline and initialize the control algorithm.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participant 1. Age ≥18.0 years old at time of consent
- Clinical diagnosis, based on investigator assessment, of T1D for \> 1 year.
- Having used an FDA approved AID system within the last 6 months (can be intermittent use).
- Currently using insulin for \>6 months.
- Willingness to switch to use an FDA-approved personal insulin for the study pump (e.g., lispro or aspart, or biosimilar FDA-approved products) as...
You likely can't join if
- The participant must not have any exclusion criteria to be eligible to participate in the study.
- Plans to start a new non-insulin glucose-lowering agent (e.g., GLP-1 receptor agonists, Symlin, DPP-4 inhibitors,). Participants may be on a stable...
- Current use of sulfonylurea medications.
- Uncontrolled microvascular complications such as active proliferative retinopathy not being treated or not responsive to current treatment.
- Current use of an SGLT-2 or SGLT-1/2 inhibitor due to risk of euglycemic DKA.
- Hemophilia or any other bleeding disorder.
See the full eligibility criteria
- Participant 1. Age ≥18.0 years old at time of consent
- Clinical diagnosis, based on investigator assessment, of T1D for \> 1 year.
- Having used an FDA approved AID system within the last 6 months (can be intermittent use).
- Currently using insulin for \>6 months.
- Willingness to switch to use an FDA-approved personal insulin for the study pump (e.g., lispro or aspart, or biosimilar FDA-approved products) as directed by the study team.
- Has one or more supportive companions knowledgeable about emergency procedures for severe hypoglycemia and able to contact emergency services and study staff who either lives with participant or located within...
- Participant not currently known to be pregnant or breastfeeding.
- If participant can become pregnant, they must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all participants of...
- Willingness to wear a Dexcom CGM during each of the study phases.
- Willingness to use the study AIDANET system (CGM, pump, and phone) during the relevant study periods.
- Willingness not to start any new non-insulin glucose-lowering agent during the trial.
- Willingness to participate in all study procedures including in person training.
- Access to internet at home and willingness to upload data during the study as needed.
- Investigator has confidence that the participant can successfully operate all study devices and can adhere to the protocol.
- Participant is proficient in reading and verbal communication in English. Participant
- The participant must not have any exclusion criteria to be eligible to participate in the study.
- Plans to start a new non-insulin glucose-lowering agent (e.g., GLP-1 receptor agonists, Symlin, DPP-4 inhibitors,). Participants may be on a stable dose of such an agent for at least the past month.
- Current use of sulfonylurea medications.
- Uncontrolled microvascular complications such as active proliferative retinopathy not being treated or not responsive to current treatment.
- Current use of an SGLT-2 or SGLT-1/2 inhibitor due to risk of euglycemic DKA.
- Hemophilia or any other bleeding disorder.
- History of severe hypoglycemic events with seizure or loss of consciousness in the last 12 months.
- History of DKA event in the last 12 months.
- Currently on peritoneal or hemodialysis.
- Currently being treated for adrenal insufficiency.
- Currently being treated for a seizure disorder.
- Hypothyroidism or hyperthyroidism that is not adequately treated.
- Use of oral or injectable steroids at the time of enrollment.
- Known ongoing adhesive intolerance that is not well managed.
- A condition, which in the opinion of the investigator or designee, would put the participant or study at risk.
- Participation in another treatment trial at the time of enrollment.
- Participant with a direct supervisor at work/school who is involved in the conduct of the trial.
The study team makes the final eligibility decision.
Where it's taking place
- Charlottesville, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Charlottesville, Virginia, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.